



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07D 221/08, 265/34, 279/14, A61K 31/445, 31/535, 31/54</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/03054</b> <b>(43) International Publication Date:</b> 30 January 1997 (30.01.97)
<b>(21) International Application Number:</b> PCT/EP96/02969 <b>(22) International Filing Date:</b> 5 July 1996 (05.07.96) <b>(30) Priority Data:</b> 9513880.6                      7 July 1995 (07.07.95)                      GB 9603988.8                      26 February 1996 (26.02.96)                      GB <b>(71) Applicant (for all designated States except AT DE US):</b> SANDOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH). <b>(71) Applicant (for DE only):</b> SANDOZ-PATENT-GMBH [DE/DE]; Humboldtstrasse 3, D-79539 Lörrach (DE). <b>(71) Applicant (for AT only):</b> SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> NEUMANN, Peter [DE/CH]; Kornhausstrasse 4, CH-3013 Berne (CH). PFAEFFLI, Paul [CH/CH]; Auf den Hallen 18, CH-4104 Oberwil (CH). SEILER, Max, Peter [CH/CH]; Bockrainweg 16, CH-4125 Riehen (CH). SWOBODA, Robert [AT/CH]; Moesliweg 30, CH-3098 Koeniz (CH).		<b>(74) Common Representative:</b> SANDOZ LTD.; Patents & Trade-marks Div., Lichtstrasse 35, CH-4002 Basle (CH). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BENZO[g]QUINOLINE DERIVATIVES  <b>(57) Abstract</b> <p>The invention provides compounds of formula (I) wherein X, Y, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are as defined in the description, and a process for preparing them. The compounds of formula (I) are useful as pharmaceuticals.</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**BENZO[g]QUINOLINE DERIVATIVES**

The present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.

More particularly the present invention provides a compound of formula I




wherein

X is = O or H,H

Y is -CH<sub>2</sub>-, -O-, -NH- or -S-,

R<sub>1</sub> is H or (C<sub>1-4</sub>)alkyl,


R<sub>2</sub> is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl or a group of formula



wherein R<sub>5</sub> is H or (C<sub>1-4</sub>)alkyl and R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> independently are H, OH, NO<sub>2</sub>,

CF<sub>3</sub>, (C<sub>1-4</sub>)alkyl, acetyl, CONR<sub>10</sub>R<sub>11</sub>, COOR<sub>12</sub> [R<sub>11</sub> and R<sub>12</sub> independently being H or (C<sub>1-4</sub>)alkyl], CN or (C<sub>1-4</sub>)alkylsulfonyl,

R<sub>3</sub> is H, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkylsulfonyl, trifluoromethylsulfonyl or a group of formula



wherein n is 1 to 5 and m is 1 to 3, and

R<sub>4</sub> is hydrogen or halogen,


in free base or acid addition salt form.

The invention includes the enantiomers as well as their mixtures, e.g. the epimeric or racemic mixtures which may be present on account of the asymmetrical carbon atoms in positions 3, 4a and 10a. The configuration [3R,4aR,10aR] is preferred.


Halogen is fluorine, chlorine, bromine or iodine, preferably chlorine or bromine.

The above-defined alkyl groups preferably represent methyl.

In one group of compounds of formula I, X, Y and R<sub>1</sub> are as defined above, R<sub>2</sub> is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl, naphthyl or a group of formula (a) as defined above or (b') or (c')




(b)



(c')


wherein  $R'_6$  and  $R'_7$  independently are H, OH,  $\text{NO}_2$ ,  $\text{CF}_3$ , acetyl,  $\text{COOR}_{12}$  ( $R_{12}$  being as defined above) or CN and  $R'_8$  is H,  $\text{NO}_2$  or CN;  $R_3$  is in position 6 and is H,  $(\text{C}_{1-4})$ alkyl, methylsulfonyl, trifluoromethylsulfonyl or a group of formula




wherein  $n$  and  $m$  are as defined above and  $R_4$  is hydrogen, the configuration in positions 4a and 10a being R.

In another group of compounds of formula I,  $X$  is  $=\text{O}$ ,  $Y$  is  $-\text{CH}_2-$  and  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined above.

In a further aspect the invention provides a process for the production of the compounds of formula I and their acid addition salts, whereby a compound of formula II



wherein  $X$ ,  $Y$ ,  $R_1$ ,  $R_3$  and  $R_4$  are as defined above and  $M$  is H or an alkali metal, is reacted with a compound of formula III




wherein  $R_2$  is as defined above, and the compounds of formula I thus obtained are recovered in free base or acid addition salt form.

The reaction can be effected according to known amide formation methods, for example as described in Example 1. In formula II, M as an alkali metal is for example sodium.

Working up the reaction mixtures obtained according to the above process and purification of the compounds thus obtained may be carried out in accordance to known procedures.

Acid addition salts may be produced from the free bases in known manner, and vice versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.

The starting compounds of formula II may be produced from the corresponding compounds of formula IV



wherein X, Y,  $R_1$ ,  $R_3$  and  $R_4$  are as defined above, for example as described in Example 1.

The compounds of formulae III and IV are known or may be produced in analogous manner to known procedures. See for example European Patent No. 77754.

Compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter

referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro using SRIF receptor expressing cell cultures and in animals, and are therefore useful as pharmaceuticals.

In particular the agents of the invention bind to somatostatin receptors. More particularly they are selective antagonists at Somatostatin sst<sub>1</sub> receptors, previously called SSTR-1 receptors (see Hoyer et al., *TIPS*, 1995, 16; 86-88), as determined in radioligand binding and second messenger studies [see for example K. Kaupmann et al., *FEBS LETTERS* 1993, 331: 53-59] where they exhibit selective affinity for sst<sub>1</sub> receptors with pIC<sub>50</sub> values between about 7.5 and 9.5.

The agents of the invention are therefore useful for treatment in anxiety, depression, schizophrenia, neurodegenerative diseases such as dementia, for the treatment of tumors and for vascular disorders and immunological diseases, as confirmed in a range of standard tests as indicated below:

At doses of about 0.3 to 3 mg/kg p.o., the agents of the invention increase exploratory behavior of mice in the open half of the half enclosed platform, a model which is predictable for anxiolytic activity (*Psychopharmacology*, 1986, 89:31-37).

In the same half enclosed platform model, the agents of the invention at the above indicated doses also increase vigilance of the mice. The compounds are therefore indicated for the treatment of depression, schizophrenia and dementia, in particular of senile dementia of the Alzheimer type (SDAT).

In the intruder mouse test [Triangle, 1982, 21: 95-105; *J. Clin. Psychiatry*, 1994, 55:9 (suppl. B) 4-7], the agents of the invention increase social investigation and reduce defensive ambivalence in the treated intruder mouse at indicated doses of about 1 to about 10 mg/kg s.c., suggesting an antidepressant profile like carbamazepine and lithium, a neuroleptic profile like clozapine and an anxiolytic profile like diazepam.

Furthermore at said doses the compounds of the invention reduce aggressive behaviour (attacks, chases, bites) in the Matched Pairs Situation test in mice [Dixon et al., J. Clin. Psychiatry 55: (9) [Suppl. B] 4-7 (1994)]. Since as mentioned above they additionally attenuate defensive behaviours in the intruder mouse test, the compounds of the invention exhibit an ethopharmacological profile which is very similar to that of carbamazepine, lithium chloride and clozapine. They are therefore indicated for the treatment of affective disorders including bipolar disorders e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired. In addition, the compounds are indicated in anxiety states, generalized anxiety as well as social and agoraphobia, as well as those behavioural states characterized by social withdrawal e.g. negative symptoms.

The agents of the invention are also effective in the treatment of various kinds of tumors, particularly of sst<sub>1</sub> receptor bearing tumors, as indicated in proliferation tests with various different cancer cell lines and in tumor growth experiments in nude mice with hormone dependent tumors [see for example: G. Weckbecker et al., Cancer Research 1994, 54: 6334-6337]. Thus the compounds are indicated in the treatment of, for example, cancers of the breast, the prostate, the colon, the pancreas, the brain and the lung (small cell lung cancer).

For all the above mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.

The agents of the invention may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same



order of activity as the free compounds.

Compounds having selective  $ssr_1$  antagonist activity, i.e. showing selective  $ssr_1$  receptor affinity in the above-mentioned binding test with  $pIC_{50}$  values  $> 7.0$ , have never previously been described in the art. Such compounds accordingly represent an entirely novel compound group.

Accordingly in a further aspect the present invention provides selective  $ssr_1$  receptor antagonists for use as pharmaceuticals, more specifically for treatment in the above-mentioned conditions, e.g. depression, anxiety and bipolar disorders.

The present invention furthermore provides a pharmaceutical composition comprising a selective  $ssr_1$  receptor antagonist, e.g. an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier. Such compositions may be formulated in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention.

Selective  $ssr_1$  receptor antagonists, e.g. agents of the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or suspensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.

For all the above indications the preferred compound is [3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-octahydro-6-methoxy-1-methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)-piperazine amide, which is the compound of example 1. Said compound has high affinity for rat  $ssr_1$  receptors ( $pIC_{50} = 9.1$ ) and recombinant human  $ssr_1$  receptors ( $pIC_{50} = 7.7$ ), without significant activity for a wide range of neurotransmitter receptors. At 1-10 mg/kg s.c., the compound clearly lowers aggressive behaviour in the above-mentioned Matched Pairs Situation test and reverses social withdrawal in the above-mentioned intruder mouse test. These effects are also observed with the standard anti-manic drugs lithium and carbamazepine at 3-30 mg/kg s.c., suggesting similar therapeutic effects in man. However, lithium and

carbamazepine were found to be less potent and are known to have considerable drawbacks such as narrow therapeutic window and slow onset of action.

The preferred indications are depression, anxiety and affective disorders, including bipolar disorders, e.g. mania.

In accordance with the foregoing, the present invention also provides the use of a selective  $ssr_1$  receptor antagonist, e.g. an agent of the invention, as a pharmaceutical, e.g. for the treatment of depression, anxiety and bipolar disorders.

Moreover the present invention provides the use of a selective  $ssr_1$  receptor antagonist, e.g. an agent of the invention, for the manufacture of a medicament for the treatment of any condition mentioned above, e.g. depression, anxiety and affective disorders.

In still a further aspect the present invention provides a method for the treatment of any condition mentioned above, e.g. depression, anxiety and bipolar disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a selective  $ssr_1$  receptor antagonist, e.g. an agent of the invention.

The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.

**Example 1: [3R, 4aR, 10aR]-1,2,3,4,4a,5,10,10a-octahydro-6-methoxy-1-methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)-piperazine amide**

- a) A mixture of 8.681 g (30 mmol) of [3R,4aR,10aR]-1-methyl-3 $\beta$ -methoxycarbonyl-6-methoxy-1,2,3,4,4a $\alpha$ ,5,10,10a $\beta$ -octahydro-benzo[g]quinoline, 36 ml of methanol, 36 ml of tetrahydrofuran and 36 ml of 1M aqueous sodium hydroxide solution is vigorously stirred during 16 hours at room temperature. After cooling to 0°, the reaction mixture is filtered

and the product is washed with cold 2-propanol and dried at 60° in high vacuum. The so obtained sodium salt of [3R,4aR,10aR]-1-methyl-6-methoxy-1,2,3,4,4a $\alpha$ ,5,10,10a $\beta$ -octahydro-benzo[g]quinoline-3 $\beta$ -carboxylic acid has a m.p. > 230° (decomposition);  $[\alpha]_D^{20} = -138.3^\circ$  (0.5 % in dimethylformamide/water 50:50).

- b) A suspension of 2.973 g (10 mmol) of the sodium salt obtained under a) in 24 ml of 38 % propane-phosphonic anhydride in dimethylformamide (30 mmol) and 10 ml of absolute pyridine is stirred during 15 minutes at room temperature. After addition of 2.07 g (10 mmol) of 1-(4-nitrophenyl)-piperazine, stirring is continued for 16 hours at room temperature and 100 ml of toluene and 100 ml of 2M aqueous ammonia are added. The precipitated crystals are filtered off, washed with water and toluene, dried and recrystallised in toluene. The resulting title compound has a m.p. of 218-221°.  $[\alpha]_D^{20} = -128.7^\circ$  (0.5 % in dimethylformamide).

The compounds of formula I below are produced in analogous manner to example 1.

In the following [3R,4aR,10aR] compounds, X is O, Y is CH<sub>2</sub>, R<sub>1</sub> is methyl, R<sub>2</sub> and R<sub>3</sub> are as indicated (OR<sub>3</sub> is in position 6) and R<sub>4</sub> is H.

Ex.	R <sub>2</sub>	R <sub>3</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	m.p.	[α] <sub>D</sub> <sup>20</sup> **
2	H	Me					120	-136.2
3	2-(c)	"				H	190	-121.4
4	"	-SO <sub>2</sub> CF <sub>3</sub>				"	174	-106.3
5	"	(4-OH-Ph)Pr				"	209	-113.6
6	4-(c)	Me				"	185	-137.0
7	2-pyrimidyl	"					213	-129.7
8	benzyl	"					130	-119.5
9	bis(4-F-Ph)-Me-	"					*	-97.9
10	(b)	"		2-NO <sub>2</sub>	H		*	-116.8
11	"	"		"	4-CF <sub>3</sub>		*	-99.5
12	"	H		4-NO <sub>2</sub>	H		223	-131.9

13	"	-SO <sub>2</sub> CF <sub>3</sub>		"	"		106	-113.6
14	"	-SO <sub>2</sub> Me		"	"		188	-123.4
15	"	Me		2-CN	"		*	-123.6
16	"	"		4-CN	"		216	-125.7
17	2-(c)	"				5-CN	205	-124.0
18	1-(d) R <sub>9</sub> = H	"					*	-121.3
19	(b)	"		4-OH	H		287	-116.7
20	"	"		4-Ac	"		214	-116.3
21	"	"		4-CF <sub>3</sub>	"		119	-110.4
22	(a)	"	Me				192	-118.3
23	"	"	H				227	-123.0
24	2-(c)	"				6-BnO	147	-100.0
25	(b)	"		4-COOMe	H		251	-124.0

26	"	"	"	4-NH <sub>2</sub> CO	"		260	-104.9
27	"	"	"	4-diEt-NH <sub>2</sub> CO	"		163	-103.5
28	"	"	"	2-CN	4-NO <sub>2</sub>		191	-121.3
29	"	"	"	3-NO <sub>2</sub>	H		95	-101.7
30	"	"	"	2-MeSO <sub>2</sub>	4-NO <sub>2</sub>		271	-92.9
31	1(d) R <sub>9</sub> = 6-CN	"	"				195	-106
32	1(d) R <sub>9</sub> = 7-CN	"	"				195	-106
33	1(d) R <sub>9</sub> = 8-Cl	"	"				245	-101

In the following racemates, X is O, Y is O, R<sub>1</sub> is methyl, R<sub>2</sub> and R<sub>3</sub> are as indicated (OR<sub>3</sub> is in position 6) and R<sub>4</sub> is H.

Ex.	R <sub>2</sub>	R <sub>3</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	m.p.	Config.
34	2-(c)	Me				H	179	(1)
35	"	"				"	167	(2)
36	(b)	"		4-NO <sub>2</sub>	H		176	(1)
37	"	"		"	"		222	(2)
38	2-(c)	"				6-CF <sub>3</sub>	154	(1)
39	"	"				"	142	(2)
40	"	"				3-CF <sub>3</sub>	138	(1)

In the following [3aR,4aR,10aR] compound, X is O, Y is CH<sub>2</sub>, R<sub>1</sub> is methyl, R<sub>2</sub> and R<sub>3</sub> are as indicated (OR<sub>3</sub> is in position 6) and R<sub>4</sub> is 9-Br.

Ex.	R <sub>2</sub>	R <sub>3</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	m.p.	[α] <sub>D</sub> <sup>20</sup> **
41	(a)	Me	Me				216	-98.6

In the following [3aR,4aR,10aR] compound, X is O, Y is CH<sub>2</sub>, R<sub>1</sub> is H, R<sub>2</sub> and R<sub>3</sub> are as indicated (OR<sub>3</sub> is in position 6) and R<sub>4</sub> is H.

Ex.	R <sub>2</sub>	R <sub>3</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	m.p.	[α] <sup>20</sup> <sub>D</sub> ***
42	(b)	Me		4-NO <sub>2</sub>	H		226	-115.5

In the following racemate, X is H,H, Y is S, R<sub>1</sub> is methyl, R<sub>2</sub> and R<sub>3</sub> are as indicated (OR<sub>3</sub> is in position 6) and R<sub>4</sub> is H.

Ex.	R <sub>2</sub>	R <sub>3</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	m.p.	Config.
43	2-(c)	Me				H	128	(2)

In the following racemate, X is O, Y is H,H, R<sub>1</sub> is methyl, R<sub>2</sub> and R<sub>3</sub> are as indicated (OR<sub>3</sub> is in position 7) and R<sub>4</sub> is H.

Ex.	R <sub>2</sub>	R <sub>3</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	m.p. (decomp.)	Config.
44	(b)	Me		4-NO <sub>2</sub>	H		284	(1)

Me = methyl

Et = Ethyl

Pr = propyl Ph = phenyl

Bn = Benzyl

Ac = acetyl

\* : amorphous

\*\* : 0.5 % in DMF

\*\*\*: 0.25% in DMF

(1) = [3RS,4aRS,10aRS] racemate

(2) = [3SR,4aRS,10aRS] racemate




**Example 45:** [3S,4aS,10aS]-1,2,3,4,4a,5,10,10a-octahydro-6-methoxy-1-methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)-piperazine amide

Optical isomer of the compound of example 1, produced in analogous manner to example 1. M.p. (HCl salt) = 254°;  $[\alpha]^{20}_D$  (free base) = + 135.3° (0.5% in DMF).

## CLAIMS:

1. A compound of formula I




wherein

X is = O or H,H

Y is -CH<sub>2</sub>-, -O-, -NH- or -S-,


R<sub>1</sub> is H or (C<sub>1-4</sub>)alkyl,

R<sub>2</sub> is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl or a group of formula



wherein R<sub>5</sub> is H or (C<sub>1-4</sub>)alkyl and R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> independently are H, OH, NO<sub>2</sub>, CF<sub>3</sub>, (C<sub>1-4</sub>)alkyl, acetyl, CONR<sub>10</sub>R<sub>11</sub>, COOR<sub>12</sub> [R<sub>11</sub> and R<sub>12</sub> independently being H or (C<sub>1-4</sub>)alkyl], CN or (C<sub>1-4</sub>)alkylsulfonyl,


$R_3$  is H,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkylsulfonyl, trifluoromethylsulfonyl or a group of formula




wherein n is 1 to 5 and m is 1 to 3,

in free base or acid addition salt form.

2. A compound of formula I according to claim 1, wherein X, Y and  $R_1$  are as defined in claim 1,  $R_2$  is H, benzyl, pyrimidyl, bis(4-fluorophenyl)methyl, naphthyl or a group of formula (a) as defined in claim 1 or of formula (b') or (c')




(b')




(c')

wherein  $R'_6$  and  $R'_7$  independently are H, OH,  $\text{NO}_2$ ,  $\text{CF}_3$ , acetyl,  $\text{COOR}_{12}$  ( $R_{12}$  being as defined in claim 1) or CN and  $R'_8$  is H,  $\text{NO}_2$  or CN,  $R_3$  is in position 6 and is H,  $(C_{1-4})$ alkyl, methylsulfonyl, trifluoromethylsulfonyl or a group of formula




wherein n and m are as defined in claim 1 and  $R_4$  is hydrogen, the configuration in positions 4a and 10a being R, in free base or acid addition salt form.

3. A compound of claim 1 which is [3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-octahydro-6-methoxy-1-methyl-benzo[g]quinoline-3-carboxylic acid 4-(4-nitro-phenyl)-piperazine amide, in free base or acid addition salt form.
4. A selective antagonist at somatostatin sst<sub>1</sub> receptors, for use as a pharmaceutical.
5. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the step of reacting a compound of formula II



wherein X, Y, R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> are as defined in claim 1 and M is H or an alkali metal, with a compound of formula III



wherein R<sub>2</sub> is as defined in claim 1, and recovering the thus obtained compound of formula I in free base or acid addition salt form.

6. A compound of anyone of claims 1 to 3, in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

7. A compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of depression, anxiety and bipolar disorders.
8. A pharmaceutical composition comprising a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
9. The use of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical, for the treatment of depression, anxiety and bipolar disorders.
10. The use of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of depression, anxiety and bipolar disorders.
11. A method for the treatment of depression, anxiety and bipolar disorders in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of anyone of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form.

# INTERNATIONAL SEARCH REPORT

International Application No  
PL./EP 96/02969

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C07D221/08 C07D265/34 C07D279/14 A61K31/445 A61K31/535 A61K31/54		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 077 754 (SANDOZ) 27 April 1983 cited in the application see claims 1-3,14,15 ---	1,6,8
A	GB,A,2 198 129 (SANDOZ LTD.) 8 June 1988 see claims 1,4,13,16 ---	1,6,8
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 3, 1985, pages 367-75, XP000608331 R. NORDMANN ET AL.: "Octahydrobenzo[g]quinolines: Potent Dopamine Agonists Which Show the Relationship between Ergolines and Apomorphine" see schemes III, IV, table II --- -/-	1
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search  30 October 1996		Date of mailing of the international search report  11. 11. 96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. ( - 31-70) 340-2040, Tx. 31 651 epo nl. Fax ( - 31-70) 340-3016		Authorized officer  Hass, C

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 96/02969

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB,A,2 160 200 (SANDOZ LTD.) 18 December 1985 see claims 3,6-8,42,50 ---	1,6,8
A	EP,A,0 641 787 (SANDOZ) 8 March 1995 see claims 1,4,8 -----	1,6,8

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/02969

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 11 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter: onal Application No

PCT/EP 96/02969

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-77754	27-04-83	AU-B- 558375	29-01-87
		AU-A- 8936782	21-04-83
		CA-A- 1200241	04-02-86
		CY-A- 1736	03-06-94
		HK-A- 107794	14-10-94
		JP-C- 1810450	27-12-93
		JP-A- 2138262	28-05-90
		JP-B- 5009430	04-02-93
		LU-A- 88619	10-07-95
		US-A- 4565818	21-01-86
		JP-C- 1610004	15-07-91
		JP-B- 2027988	20-06-90
		JP-A- 58083679	19-05-83
GB-A-2198129	08-06-88	AU-B- 604512	20-12-90
		AU-A- 8140987	26-05-88
		BE-A- 1003219	04-02-92
		CH-A- 677668	14-06-91
		DE-A- 3738577	28-07-88
		FR-A- 2607134	27-05-88
		JP-A- 63150264	22-06-88
		LU-A- 87047	13-06-88
		NL-A- 8702680	16-06-88
		SE-A- 8704551	22-05-88
GB-A-2160200	18-12-85	AT-B- 394717	10-06-92
		AU-B- 582751	13-04-89
		AU-A- 4345885	19-12-85
		BE-A- 902600	06-12-85
		CA-A- 1285561	02-07-91
		CH-A- 666031	30-06-88
		DE-A- 3520104	12-12-85
		FR-A- 2565586	13-12-85
		HK-A- 11891	22-02-91
		IE-B- 58398	08-09-93
		JP-C- 1865038	26-08-94
		JP-A- 61001676	07-01-86
		LU-A- 85941	24-01-86
		NL-A- 8501526	02-01-86
		SE-B- 465428	09-09-91

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/02969

Patent document cited in search report	Publication date	Patent family members)	Publication date
GB-A-2160200		SE-A- 8502865 US-A- 4656167	13-12-85 07-04-87
EP-A-641787	08-03-95	DE-A- 4329776 AU-A- 7164394 CA-A- 2117656 CN-A- 1105998 CZ-A- 9402110 FI-A- 944012 HU-A- 71117 JP-A- 7165736 NO-A- 943230 PL-A- 304878 SK-A- 104894	09-03-95 16-03-95 04-03-95 02-08-95 15-03-95 04-03-95 28-11-95 27-06-95 06-03-95 06-03-95 10-05-95